Mizuho Securities analyst Uy Ear maintained a Buy rating on Cabaletta Bio (CABA – Research Report) yesterday and set a price target of $10.00. The company’s shares closed yesterday at $7.75.
According to TipRanks, Ear is a 4-star analyst with an average return of 11.1% and a 28.95% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Evolus.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cabaletta Bio with a $13.80 average price target.
See the top stocks recommended by analysts >>
CABA market cap is currently $231.7M and has a P/E ratio of -4.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Read More on CABA:
- Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks
- Cabaletta Bio price target raised to $18 from $14 at Evercore ISI
- Morgan Stanley upgrades Cabaletta Bio ahead of new drug filing
